Vaccine strategies against human cytomegalovirus infection

References

• Dolan A, Cunningham C, Hector RD et al. Genetic content of wild-type human cytomegalovirus. J. Gen. Virol.85(Pt 5), 1301–1312 (2004).
   PubMed Web of Science ®Google Scholar
• Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine19(11–12), 1356–1362 (2001).
   PubMed Web of Science ®Google Scholar
• Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr. Infect. Dis. J.11(2), 93–99 (1992).
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect. Dis.4(12), 725–738 (2004).
   PubMed Web of Science ®Google Scholar
• Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin. Infect. Dis.39(2), 233–239 (2004).
   PubMed Web of Science ®Google Scholar
• Komanduri KV, Donahoe SM, Moretto WJ et al. Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects. Virology279(2), 459–470 (2001).
   PubMed Web of Science ®Google Scholar
• Gerna G, d’Arminio Monforte A, Zavattoni M et al. Sharp drop in the prevalence of human cytomegalovirus leuko-DNAemia in HIV-infected patients following highly active antiretroviral therapy. AIDS12(1), 118–120 (1998).
   PubMed Web of Science ®Google Scholar
• Steininger C, Puchhammer-Stockl E, Popow-Kraupp T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J. Clin. Virol.37(1), 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Schrier R, McCune JM et al. Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy. J. Infect. Dis.183(9), 1399–1404 (2001).
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Vaccine for the 21st Century. National Academy Press, DC, USA (2000).
   Google Scholar
• Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol.2(11), 831–844 (2002).
   PubMed Web of Science ®Google Scholar
• Borysiewicz LK, Hickling JK, Graham S et al. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J. Exp. Med.168(3), 919–931 (1988).
   PubMed Web of Science ®Google Scholar
• Falk CS, Mach M, Schendel DJ et al. NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. J. Immunol.169(6), 3257–3266 (2002).
   PubMed Web of Science ®Google Scholar
• Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Ann. Rev. Immunol.17, 189–220 (1999).
   PubMed Web of Science ®Google Scholar
• Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med.320(26), 1731–1735 (1989).
   PubMed Web of Science ®Google Scholar
• Yeager AS, Grumet FC, Hafleigh EB et al. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J. Pediatr.98(2), 281–287 (1981).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Congenital cytomegalovirus infection and its prevention. Clin. Infect. Dis.38(7), 1038–1039 (2004).
   PubMed Web of Science ®Google Scholar
• Boppana SB, Polis MA, Kramer AA, Britt WJ, Koenig S. Virus-specific antibody responses to human cytomegalovirus (HCMV) in human immunodeficiency virus type 1-infected persons with HCMV retinitis. J. Infect. Dis.171(1), 182–185 (1995).
   PubMed Web of Science ®Google Scholar
• Urban M, Klein M, Britt WJ, Hassfurther E, Mach M. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J. Gen. Virol.77(Pt 7), 1537–1547 (1996).
   PubMed Web of Science ®Google Scholar
• Mach M, Kropff B, Dal Monte P, Britt W. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J. Virol.74(24), 11881–11892 (2000).
   PubMed Web of Science ®Google Scholar
• Rapp M, Messerle M, Buhler B et al. Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J. Virol.66(7), 4399–4406 (1992).
   PubMed Web of Science ®Google Scholar
• Schleiss MR, Bourne N, Stroup G et al. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J. Infect. Dis.189(8), 1374–1381 (2004).
   PubMed Web of Science ®Google Scholar
• Snydman DR, Werner BG, Meissner HC et al. Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatr. Infect. Dis. J.14(1), 34–40 (1995).
   PubMed Web of Science ®Google Scholar
• Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl. J. Med.353(13), 1350–1362 (2005).
   PubMed Web of Science ®Google Scholar
• Snydman DR. Review of the efficacy of cytomegalovirus immune globulin in the prophylaxis of CMV disease in renal transplant recipients. Transplant Proc.25(5 Suppl. 4), 25–26 (1993).
   PubMedGoogle Scholar
• Falagas ME, Snydman DR, Ruthazer R et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin. Transplant.11(5 Pt 1), 432–437 (1997).
   PubMed Web of Science ®Google Scholar
• Valantine HA. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin. Transplant Proc.27(5 Suppl. 1), 49–57 (1995).
   PubMed Web of Science ®Google Scholar
• Bowden RA, Sayers M, Flournoy N et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N. Engl. J. Med.314(16), 1006–1010 (1986).
   PubMed Web of Science ®Google Scholar
• Volpi A, Pica F, Gentile G et al. Neutralizing antibody response against human cytomegalovirus in allogeneic bone marrow-transplant recipients. J. Infect. Dis.180(5), 1747–1748 (1999).
   PubMed Web of Science ®Google Scholar
• Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transpl. Infect. Dis.1(3), 165–178 (1999).
   PubMedGoogle Scholar
• Messori A, Rampazzo R, Scroccaro G, Martini N. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. Bone Marrow Transplant13(2), 163–167 (1994).
   PubMed Web of Science ®Google Scholar
• Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients – a meta-analysis. Clin. Transplant.8(1), 10–18 (1994).
   PubMed Web of Science ®Google Scholar
• Schoppel K, Schmidt C, Einsele H, Hebart H, Mach M. Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J. Infect. Dis.178(5), 1233–1243 (1998).
   PubMed Web of Science ®Google Scholar
• Reddehase MJ, Weiland F, Munch K et al. Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J. Virol.55(2), 264–273 (1985).
   PubMed Web of Science ®Google Scholar
• Lacey SF, Diamond DJ, Zaia JA. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol. Blood Marrow Transplant10(7), 433–447 (2004).
   PubMed Web of Science ®Google Scholar
• Sester M, Sester U, Gartner B et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation71(9), 1287–1294 (2001).
   PubMed Web of Science ®Google Scholar
• Sester U, Gartner BC, Wilkens H et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am. J. Transplant.5(6), 1483–1489 (2005).
   PubMed Web of Science ®Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med.333(16), 1038–1044 (1995).
   PubMed Web of Science ®Google Scholar
• Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science257(5067), 238–241 (1992).
   PubMed Web of Science ®Google Scholar
• Gyulai Z, Endresz V, Burian K et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J. Infect. Dis.181(5), 1537–1546 (2000).
   PubMed Web of Science ®Google Scholar
• Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr. Infect. Dis. J.17(3), 200–206 (1998).
   PubMed Web of Science ®Google Scholar
• Wills MR, Carmichael AJ, Weekes MP et al. Human virus-specific CD8+ CTL clones revert from CD45ROhigh to CD45RAhighin vivo: CD45RAhighCD8+ T cells comprise both naive and memory cells. J. Immunol.162(12), 7080–7087 (1999).
   PubMed Web of Science ®Google Scholar
• Bunde T, Kirchner A, Hoffmeister B et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med.201(7), 1031–1036 (2005).
   PubMed Web of Science ®Google Scholar
• Gratama JW, van Esser JW, Lamers CH et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood98(5), 1358–1364 (2001).
   PubMed Web of Science ®Google Scholar
• Heijnen IA, Barnett D, Arroz MJ et al. Enumeration of antigen-specific CD8+ T lymphocytes by single-platform, HLA tetramer-based flow cytometry: a European multicenter evaluation. Cytometry B Clin. Cytom.62(1), 1–13 (2004).
   PubMedGoogle Scholar
• Hobeika AC, Morse MA, Osada T et al. Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J. Immunother.28(1), 63–72 (2005).
   PubMed Web of Science ®Google Scholar
• Elkington R, Walker S, Crough T et al.Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J. Virol.77(9), 5226–5240 (2003).
   PubMed Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med.202(5), 673–685 (2005).
   PubMed Web of Science ®Google Scholar
• Manley TJ, Luy L, Jones T et al. Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood104(4), 1075–1082 (2004).
   PubMed Web of Science ®Google Scholar
• Tu W, Chen S, Sharp M et al. Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J. Immunol.172(5), 3260–3267 (2004).
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood99(11), 3916–3922 (2002).
   PubMed Web of Science ®Google Scholar
• Gamadia LE, Remmerswaal EB, Weel JF et al. Primary immune responses to human CMV: a critical role for IFN-γ-producing CD4+ T cells in protection against CMV disease. Blood101(7), 2686–2692 (2003).
   PubMed Web of Science ®Google Scholar
• van Zanten J, Harmsen MC, van der Meer P et al. Proliferative T cell responses to four human cytomegalovirus-specific proteins in healthy subjects and solid organ transplant recipients. J. Infect. Dis.172(3), 879–882 (1995).
   PubMed Web of Science ®Google Scholar
• He H, Rinaldo CR Jr, Morel PA. T cell proliferative responses to five human cytomegalovirus proteins in healthy seropositive individuals: implications for vaccine development. J. Gen. Virol.76(Pt 7), 1603–1610 (1995).
   PubMed Web of Science ®Google Scholar
• Beninga J, Kropff B, Mach M. Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J. Gen. Virol.76(Pt 1), 153–160 (1995).
   PubMed Web of Science ®Google Scholar
• Elkington R, Shoukry NH, Walker S et al. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur. J. Immunol.34(11), 3216–3226 (2004).
   PubMed Web of Science ®Google Scholar
• Davignon JL, Castanie P, Yorke JA et al. Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro.J. Virol.70(4), 2162–2169 (1996).
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Is there a formula for an effective CMV vaccine? J. Clin. Virol.25(Suppl. 2), S13–S21 (2002).
   Google Scholar
• Sachs GW, Simmons RL, Balfour HH Jr. Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates. Vaccine2(3), 215–218 (1984).
   PubMedGoogle Scholar
• Plotkin SA. Vaccination against cytomegalovirus. Arch. Virol. Suppl.17, 121–134 (2001).
   Google Scholar
• Plotkin SA, Starr SE, Friedman HM et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann. Intern. Med.114(7), 525–531 (1991).
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Higgins R, Kurtz JB et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation58(11), 1176–1178 (1994).
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Sinclair E, Bredt B et al. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J. Clin. Virol.35(3), 332–337 (2006).
   PubMed Web of Science ®Google Scholar
• Khanna R, Diamond DJ. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol. Med.12(1), 26–33 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Sinclair E, Bredt B et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine24(25), 5311–5319 (2006).
   PubMed Web of Science ®Google Scholar
• Kemble G, Duke G, Winter R, Spaete R. Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J. Virol.70(3), 2044–2048 (1996).
   PubMed Web of Science ®Google Scholar
• Mocarski ES Jr, Kemble GW. Recombinant cytomegaloviruses for study of replication and pathogenesis. Intervirology39(5–6), 320–330 (1996).
   PubMed Web of Science ®Google Scholar
• Gonczol E, Plotkin S. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin. Biol. Ther.1(3), 401–412 (2001).
   PubMed Web of Science ®Google Scholar
• Heineman TC, Schleiss M, Bernstein DI et al. A Phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J. Infect. Dis.193(10), 1350–1360 (2006).
   PubMed Web of Science ®Google Scholar
• Pepperl-Klindworth S, Plachter B. Current perspectives in vaccine development. In: Cytomegaloviruses Molecular Biology and Immunology. Reddehase M (Ed.). Caister Academic Press Ltd, Norfolk, UK 551–572 (2006).
   Google Scholar
• Schleiss M. Progress in cytomegalovirus vaccine development. Herpes12(3), 66–75 (2005).
   PubMedGoogle Scholar
• Pass RF, Duliege AM, Boppana S et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis.180(4), 970–975 (1999).
   PubMed Web of Science ®Google Scholar
• Frey SE, Harrison C, Pass RF et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J. Infect. Dis.180(5), 1700–1703 (1999).
   PubMed Web of Science ®Google Scholar
• Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr. Infect. Dis. J.21(2), 133–138 (2002).
   PubMed Web of Science ®Google Scholar
• Zhang C, Pass RF. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine. Vaccine23(4), 507–510 (2004).
   PubMed Web of Science ®Google Scholar
• Skinner MA, Laidlaw SM, Eldaghayes I, Kaiser P, Cottingham MG. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev. Vaccines4(1), 63–76 (2005).
   PubMed Web of Science ®Google Scholar
• Adler SP, Plotkin SA, Gonczol E et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J. Infect. Dis.180(3), 843–846 (1999).
   PubMed Web of Science ®Google Scholar
• Berencsi K, Gyulai Z, Gonczol E et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J. Infect. Dis.183(8), 1171–1179 (2001).
   PubMed Web of Science ®Google Scholar
• Berencsi K, Gonczol E, Endresz V et al. The N-terminal 303 amino acids of the human cytomegalovirus envelope glycoprotein B (UL55) and the exon 4 region of the major immediate early protein 1 (UL123) induce a cytotoxic T-cell response. Vaccine14(5), 369–374 (1996).
   PubMed Web of Science ®Google Scholar
• Shanley JD, Wu CA. Mucosal immunization with a replication-deficient adenovirus vector expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic immunity. Vaccine21(19–20), 2632–2642 (2003).
   PubMed Web of Science ®Google Scholar
• Wang Z, La Rosa C, Maas R et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J. Virol.78(8), 3965–3976 (2004).
   PubMed Web of Science ®Google Scholar
• Wang Z, La Rosa C, Lacey SF et al. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J. Clin. Virol.35(3), 324–331 (2006).
   PubMed Web of Science ®Google Scholar
• Wang Z, Rosa CL, Li Z et al. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine25(6), 1132–1141 (2007).
   PubMed Web of Science ®Google Scholar
• Schleiss MR, Lacayo JC, Belkaid Y et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J. Infect. Dis.195(6), 789–798 (2007).
   PubMed Web of Science ®Google Scholar
• Robinson HL, Pertmer TM. DNA vaccines for viral infections: basic studies and applications. Adv. Virus Res.55, 1–74 (2000).
   PubMed Web of Science ®Google Scholar
• Endresz V, Burian K, Berencsi K et al. Optimization of DNA immunization against human cytomegalovirus. Vaccine19(28–29), 3972–3980 (2001).
   PubMed Web of Science ®Google Scholar
• Endresz V, Kari L, Berencsi K et al. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine17(1), 50–58 (1999).
   PubMed Web of Science ®Google Scholar
• Selinsky C, Luke C, Wloch M et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum. Vaccin.1(1), 16–23 (2005).
   PubMed Web of Science ®Google Scholar
• Evans TG, Wloch M, Hermanson G et al. Phase I trial of a bivalent, formulated plasmid DNA CMV vaccine for use in the transplant population. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, October 30–November 2, 2004 (Abstract).
   Google Scholar
• Wloch MK, Reyes LR, Boutsaboualoy S et al. Immunogenicity of a DNA-based CMV vaccine in humans. Presented at: 43rd Annual Meeting of Infectious Disease Society of America. CA, USA, October 6–9, 2005.
   Google Scholar
• Gandhi MK, Wills MR, Sissons JG, Carmichael AJ. Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. Blood Rev.17(4), 259–264 (2003).
   PubMed Web of Science ®Google Scholar
• Morello CS, Ye M, Hung S, Kelley LA, Spector DH. Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge. J. Virol.79(1), 159–175 (2005).
   PubMed Web of Science ®Google Scholar
• Paston SJ, Dodi IA, Madrigal JA. Progress made towards the development of a CMV peptide vaccine. Hum. Immunol.65(5), 544–549 (2004).
   PubMed Web of Science ®Google Scholar
• BenMohamed L, Krishnan R, Longmate J et al. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. Hum. Immunol.61(8), 764–779 (2000).
   PubMed Web of Science ®Google Scholar
• La Rosa C, Wang Z, Brewer JC et al. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood100(10), 3681–3689 (2002).
   PubMed Web of Science ®Google Scholar
• Stinski MF. Human cytomegalovirus: glycoproteins associated with virions and dense bodies. J. Virol.19(2), 594–609 (1976).
   PubMed Web of Science ®Google Scholar
• Vonka V, Anisimova E, Macek M. Replication of cytomegalovirus in human epitheloid diploid cell line. Arch. Virol.52(4), 283–296 (1976).
   PubMed Web of Science ®Google Scholar
• Gerna G, Gullino M, Gerna MT, Achilli G. Differential ultrastructural elements in human cytomegalovirus and Herpes simplex virus replication in cultures of human cells. G. Batteriol. Virol. Immunol.68(1–6), 50–64 (1975).
   PubMedGoogle Scholar
• Pepperl-Klindworth S, Frankenberg N, Plachter B. Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles. J. Clin. Virol.25(Suppl. 2), S75–S85 (2002).
   Google Scholar
• Pepperl S, Munster J, Mach M, Harris JR, Plachter B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J. Virol.74(13), 6132–6146 (2000).
   PubMed Web of Science ®Google Scholar
• Pepperl-Klindworth S, Frankenberg N, Riegler S, Plachter B. Protein delivery by subviral particles of human cytomegalovirus. Gene Ther.10(3), 278–284 (2003).
   PubMed Web of Science ®Google Scholar
• Thomson SA, Khanna R, Gardner J et al. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc. Natl Acad. Sci. USA92(13), 5845–5849 (1995).
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Bharadwaj M, Tellam J et al. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res.64(4), 1483–1489 (2004).
   PubMed Web of Science ®Google Scholar
• Rist M, Cooper L, Elkington R et al.Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy. Eur. J. Immunol.35(3), 996–1007 (2005).
   PubMed Web of Science ®Google Scholar
• Riddell SR, Warren EH, Gavin MA et al. Immunotherapy of human viral and malignant diseases with genetically modified T-cell clones. Cancer J.6(Suppl. 3), S250–S258 (2000).
   Google Scholar
• Waner JL, Weller TH. Analysis of antigenic diversity among human cytomegaloviruses by kinetic neutralization tests with high-titered rabbit antisera. Infect. Immun.21(1), 151–157 (1978).
   PubMed Web of Science ®Google Scholar
• Baboonian C, Blake K, Booth JC, Wiblin CN. Complement-independent neutralising monoclonal antibody with differential reactivity for strains of human cytomegalovirus. J. Med. Virol.29(2), 139–145 (1989).
   PubMed Web of Science ®Google Scholar
• Simpson JA, Chow JC, Baker J et al. Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J. Virol.67(1), 489–496 (1993).
   PubMed Web of Science ®Google Scholar
• Klein M, Schoppel K, Amvrossiadis N, Mach M. Strain-specific neutralization of human cytomegalovirus isolates by human sera. J. Virol.73(2), 878–886 (1999).
   PubMed Web of Science ®Google Scholar
• Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N. Engl. J. Med.344(18), 1366–1371 (2001).
   PubMed Web of Science ®Google Scholar
• Smith MG. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc. Soc. Exp. Biol. Med.92(2), 424–430 (1956).
   PubMed Web of Science ®Google Scholar
• Craig JM, Macauley JC, Weller TH, Wirth P. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc. Soc. Exp. Biol. Med.94(1), 4–12 (1957).
   PubMed Web of Science ®Google Scholar
• Quinnan GV Jr, Delery M, Rook AH et al. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann. Intern. Med.101(4), 478–483 (1984).
   PubMed Web of Science ®Google Scholar
• Reddehase MJ, Mutter W, Munch K, Buhring HJ, Koszinowski UH. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol.61(10), 3102–3108 (1987).
   PubMed Web of Science ®Google Scholar
• Koszinowski UH, Reddehase MJ, Keil GM et al. Molecular analysis of herpesviral gene products recognized by protective cytolytic T lymphocytes. Immunol. Lett.16(3–4), 185–192 (1987).
   PubMed Web of Science ®Google Scholar
• Berencsi K, Rando RF, deTaisne C et al. Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB. J. Gen. Virol.74(Pt 11), 2507–2512 (1993).
   PubMed Web of Science ®Google Scholar
• Pande H, Campo K, Tanamachi B, Forman SJ, Zaia JA. Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein. Scand. J. Infect. Dis. Suppl.99, 117–120 (1995).
   PubMedGoogle Scholar
• Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood90(5), 1751–1767 (1997).
   PubMed Web of Science ®Google Scholar
• Adler SP, Starr SE, Plotkin SA et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis.171(1), 26–32 (1995).
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Starr SE, Friedman HM, Gonczol E, Weibel RE. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J. Infect. Dis.159(5), 860–865 (1989).
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Smiley ML, Friedman HM et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet1(8376), 528–530 (1984).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Schleiss MR, Berencsi K et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J. Infect. Dis.185(5), 686–690 (2002).
   PubMed Web of Science ®Google Scholar
• BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology106(1), 113–121 (2002).
   PubMed Web of Science ®Google Scholar